DDInter257 DDInter542
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Butalbital {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Diphenhydramine {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Diphenhydramine {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Diphenhydramine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Butalbital {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Procarbazine
Procarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dicoumarol
Butalbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) resembles {v} (Compound) Dicoumarol
Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Dicoumarol (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound) and Warfarin (Compound) resembles Dicoumarol (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dicoumarol (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) resembles Dicoumarol (Compound)